Peroxisome proliferator-activated receptor-γ in the renal mesangium

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 2, 2002, Pages 191-195

  Hsueh, Willa A ^a   Nicholas, Susanne B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORT; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; MESANGIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; GLOMERULAR MESANGIUM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INSULIN; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036189868     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200203000-00010     Document Type: Review

References (56)

1. Roles of PPARs in health and disease
2. Co-activators and co-repressors in the integration of transcriptional responses
3. Peroxisome proliferator activated receptor agonists
4. The role of fibric acids in atherosclerosis
5. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
6. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells
7. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC-/+ mice
8. Expression and function of PPARγ in rat and human vascular smooth muscle cells
9. The PPARs and PXRs: Nuclear xenobiotic receptors that define novel hormone signaling pathways
10. PPARγ and the treatment of insulin resistance
11. Diminished insulin receptor autophosphorylation and elevated PC-1 levels in obese insulin-resistance rhesus monkeys
12. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
13. PPARγ and the treatment of insulin resistance
14. The circulating proinsulin-like components
15. The hormone resistin links obesity to diabetes
16. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
17. Fuel selection in human skeletal muscle in insulin resistance: A reexamination
18. CAP defines a second signaling pathway required for insulin-stimulated glucose transport
19. Retinoid X receptor expression in skeletal muscle of nondiabetic obese and type 2 diabetic individuals
20. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation
21. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
22. Thiazolidinediones: Tools for the research of metabolic syndrome X
23. Insulin resistance in healthy Mexican Americans is associated with coronary artery endothelial dysfunction
24. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
25. C-reactive protein is more strongly related to post-glucose load glucoses than with fasting glucose: The insulin resistance atherosclerosis study (IRAS)
26. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
27. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition
28. Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation
29. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
30. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
31. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
32. Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators
33. Loss-of-function mutations in PPAR gamma associated with human colon cancer
34. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase
35. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization
36. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
37. Troglitazone stimulates basolateral rheogenic Na+/HCO3 cotransport activity in rabbit proximal straight tubules
38. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus
39. Rosiglitazone-mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in Type 2 Diabetes patients
40. Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism but not hypertension elevated catecholamine levels or increased sodium retention in conscious normal rats
41. Receptor-mediated regional sympathetic nerve activation by leptin
42. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
43. The effect of antihypertensive drugs on vascular compliance
44. Dominant negative mutations in human PPARγ associated with severe insulin resistance diabetes mellitus and hypertension
45. Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats
46. TGF-beta in diabetic kidney disease: Role of novel signaling pathways
47. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy
48. Association of TGF-beta signaling in angiotensin II-induced PAI-1 mRNA upregulation in mesangial cells: Role of PKC
49. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
50. Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells
51. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
52. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
53. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycemic control in Type 2 diabetic patients
54. Comparative effects of pioglitazone glibenclamide and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
55. Prostaglandin J(2) inhibition of mesangial cell iNOS expression
56. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats